articleNew England Journal of MedicineDec 18, 2019BRONZE OA

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

IRIsabelle Ray‐CoquardPPPatricia PautierSPSandro PignataDPDavid PérolAGAntonio González-Martı́n

Université Claude Bernard Lyon 1 · Health Services and Performance Research Laboratory

PubMed
Indexed incrossrefpubmed

Abstract

Background

mutation status is unknown.

Methods

mutation status. Patients were randomly assigned in a 2:1 ratio to receive olaparib tablets (300 mg twice daily) or placebo for up to 24 months; all the patients received bevacizumab at a dose of 15 mg per kilogram of body weight every 3 weeks for up to 15 months in total. The primary end point was the time from randomization until investigator-assessed disease progression or death.

Citation impact

2,014
total citations
FWCI
89.59
Percentile
100%
References
32
Citations per year

Authors

30

Topics & keywords

Topics
Keywords
  • Olaparib
  • Bevacizumab
  • Ovarian cancer
  • Medicine
  • Oncology
  • BRCA mutation
  • Maintenance therapy
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding